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Background: The etiology of cancer involves a complex series of genetic and
environmental conditions. To better represent and study the intricate genetics of
cancer onset and progression, we construct a network of biological interactions to
search for groups of genes that compose cancer-related modules. Three cancer
expression datasets are investigated to prioritize genes and interactions associated
with cancer outcomes. Using a graph-based approach to search for communities of
phenotype-related genes in microarray data, we find modules of genes associated
with cancer phenotypes in a weighted interaction network.
Results: We implement Walktrap, a random-walk-based community detection
algorithm, to identify biological modules predisposing to tumor growth in 22
hepatocellular carcinoma samples (GSE14520), adenoma development in 32
colorectal cancer samples (GSE8671), and prognosis in 198 breast cancer patients
(GSE7390). For each study, we find the best scoring partitions under a maximum
cluster size of 200 nodes. Significant modules highlight groups of genes that are
functionally related to cancer and show promise as therapeutic targets; these include
interactions among transcription factors (SPIB, RPS6KA2 and RPS6KA6), cell-cycle
regulatory genes (BRSK1, WEE1 and CDC25C), modulators of the cell-cycle and
proliferation (CBLC and IRS2) and genes that regulate and participate in the map-
kinase pathway (MAPK9, DUSP1, DUSP9, RIPK2). To assess the performance of Walktrap
to find genomic modules
(Walktrap-GM), we evaluate our results against other tools recently developed to
discover disease modules in biological networks. Compared with other highly cited
module-finding tools, jActiveModules and Matisse, Walktrap-GM shows strong
performance in the discovery of modules enriched with known cancer genes.
Conclusions: These results demonstrate that the Walktrap-GM algorithm identifies
modules significantly enriched with cancer genes, their joint effects and promising
candidate genes. The approach performs well when evaluated against similar tools
and smaller overall module size allows for more specific functional annotation and
facilitates the interpretation of these modules.
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Cancer biology involves an intricate series of genetic and environmental interactions that
act in concert to influence the onset and progression of disease. The complex nature of
this information motivates the search for analytical tools that can model these interactions
to examine associations between gene interactions and cancer. Network-based studies
facilitate these genotype-phenotype investigations by integrating evidence of biological
interactions from high throughput experiments, the literature, and a growing number of
online databases, to improve the prioritization of disease genes and their interactions.
Gene set enrichment approaches leverage genomic interaction and pathway informa-
tion to enable the study of putative genes in the context of their biological processes.
Gene Set Enrichment Analysis (GSEA) [1] is a computational method that considers a
priori defined gene sets to investigate expression data for significantly enriched sets of
genes or pathways. GSEA focuses on the significance of groups of interacting genes
rather than individual genes; and variations have been developed to improve statistical
validity [2-5] and to use more granular methods to study pathway activity [6-9]. Such
approaches allow interpretation of significant genes in the setting of their pathway
interactions and functional relevance; however, they are limited in their ability to search
for significantly expressed genes that form a small component of large pathways or
interact across multiple gene sets.
Network analyses provide a framework to study genes in the context of interactions de-
rived from multiple data sources and integrated as a global interactome. Several studies
evaluate the topology of disease genes in global interaction networks and have found that
related disease genes are more likely to interact, and that cancer genes are associated with
high network centrality [10-12]. Building on the hypothesis that neighboring genes within
an interaction network share a common biological function, other network studies seed
known disease genes in functional networks combining evidence from the literature, func-
tional annotation, genomic distances, or genetic variation data (i.e., GWAS, SNP, eQTL),
to search for nearby putative genes [13-15]. Related work integrates experimental data in
the interaction network, for example, significant genes from regulatory or proteomic
experiments, to discover candidate genes given their proximity to query genes [16-18].
Further graph-based approaches search for densely connected communities within
interaction networks, using the structure of the network and weights derived from
experimental data to find modules significantly associated with phenotypes of interest.
Dittrich and colleagues [19] implement a Steiner tree to find parsimonious subnetworks
of cancer-related genes in microarray studies. The tree is an optimally connected sub-
graph spanning an interactome weighted by expression data. Ideker et al. and Chuang
et al. [20,21] apply a simulated annealing algorithm to identify significant subgraphs
associated with cancer in a protein interaction network. The algorithm initiates module
generation with seed genes and iteratively adds nearby proteins with significant p-values
to the subnetwork, until an optimal score is reached reflecting differential activity of the
module in the expression data. Ulitsky and Shamir [22] use a seed-based clustering algo-
rithm to discover significant modules in yeast and human cell cycle data. They provide
multiple heuristics to generate seeds in the network and build modules based on similarity
in expression values. These studies conclude that mining for dense subgraphs of signifi-
cant genes within interaction networks can reveal modules of genomic interactions that
are functionally relevant to specific phenotypes of interest.
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shown strong performance in the prioritization of disease genes and when evaluated
against other graph-clustering algorithms used to partition complex networks [23-25].
Transition probabilities generated by the random walk are drawn upon to calculate
distances between network nodes that can be used to prioritize genes or as metrics for
clustering algorithms. Kholer et al. [14] apply a random walk in a functional interaction
network to identify novel disease genes by their proximity to known disease genes
based on genome mapping, eQTL and interaction data. They conclude that random
walks outperform other distance-based methods in prioritizing related disease genes,
and similar approaches have been applied in genome-phenome networks [26,27]. Tu
et al. [28] employ a heuristic random walk in an integrated network to find regulatory
modules in gene expression data, identifying the most likely path from quantitative trait
loci to a candidate gene. The Markov Clustering (MCL) algorithm, based on random
walks, has been applied to cluster proteomic and expression data using similar expres-
sion profiles [29], and to search for gene signatures in cancer expression data [30].
Komurov et al. [23,31] implement a random walk algorithm to prioritize cancer genes
and hierarchically cluster expression data. These studies show the random walk is well-
adapted to genome studies in interaction networks and can be used to define distances
between nodes that reflect correlation or relevance of interaction between nodes.
The implementation of random walks varies based on optimization strategies, greedy-
search heuristics and the calculation of distance metrics. We use a random-walk algo-
rithm, Walktrap [32], that is optimized for large networks and integrates a community
search using distances derived from transition probabilities. We develop a scoring method
to rank significant modules, and configure the algorithm to improve the search for
informative modules by including a series of stopping criteria in the merge process, using
modularity, module size and maximum module score to guide clustering. The random
walk algorithm adapted to genomic modules (Walktrap-GM), is applied to guide a semi-
supervised search for cancer-related modules in an expression-weighted interactome.
Walktrap-GM demonstrates strong performance compared with similar tools developed
to identify subnetworks of disease genes in interaction networks and highlights the
potential role of candidate genes and their interactions in cancer.Methods
We employ a graph-based random walk algorithm in an integrated interaction
network to mine expression data for modules of genes associated with cancer
outcomes. First, metabolic, signaling, and protein interactions from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) [33] and the Human Protein Reac-
tion Database (HPRD) [34] are used to construct a global network of biological
interactions. Edge weights are derived from expression data from three public
datasets with multiple cancer outcomes: breast cancer, hepatocellular carcinoma
and colorectal adenoma. We apply a random walk algorithm to these networks to
discover modules of closely interconnected genes and build communities using
distances derived from the random walk process. Finally, a score is calculated for
each community and modules are ranked by significance. These methods are
summarized in Figure 1.
Figure 1 Flow diagram of network-based expression analysis. Three cancer datasets from GEO and
interactions from HPRD and KEGG are integrated in a weighted interaction network. The Walktrap random
walk builds modules based on transition probabilities generated from the random walk process. The
modules are assessed for their significance compared to a random distribution of differential expression
values per module.
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Three cancer datasets were downloaded from the Gene Expression Omnibus (GEO)
[35] covering onset of breast cancer prognosis (BC), hepatocellular carcinoma (HCC),
and adenoma development in colorectal cancer (CCA). Data were selected to represent
different stages of cancer onset and development, by the availability of paired samples
comparing normal and adjacent tissues, and detailed prognosis data. We include three
recent, large case–control studies from expression studies generated by common
platforms, Affymetrix U133A and U133A 2.0 arrays. GSE14520 is a study of hepatocel-
lular carcinoma conducted by Roessler et al. [36], consisting of 22 paired tumor and
non-tumor expression profiles using the Affymetrix HG-U133A 2.0 array. Desmedt
et al. [37] published an expression dataset consisting of 198 samples to independently
validate a 76-gene prognostic breast cancer signature as part of the TRANSBIG project
(GSE7390). A total of 198 profiles from lymph node-negative patients (N-) were
analyzed on the Affymetrix HG-U133A array, and each profile was associated with the
Adjuvant!Online clinical risk index, identifying patients at high risk for distant
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colonic adenomas and normal mucosa of 32 colonoscopy patients and analyzed expres-
sion profiles using Affymetrix HG-U133A 2.0 arrays (GSE8671). Normal tissue was
compared to colonic adenoma cancer precursors. These data are summarized in
Table 1.
We calculate normalized, log-transformed fold-change values and p-values com-
paring paired normal versus disease tissue in HCC and CCA, and high-risk versus
low-risk samples in BC. Log odds of differential expression were calculated by em-
pirical Bayes and corresponding p-values were corrected for multiple testing using
the Benjamini and Hochberg false discovery rate [39]. Processing of expression
values and phenotype data and differential statistical analyses were performed in R
using the GEOquery [40] and limma [41,42] packages in Bioconductor [43].Network construction
The interactome for this study was built by extracting human interactions from KEGG
and HPRD. KEGG relations were parsed from KGML files, representing 32,563 unique
interactions. Metabolic reactions were defined as a relation between two neighboring
enzymes that share a common metabolite; signaling reactions were defined as two
genes that participate in a signaling cascade where both genes share a reaction event. A
total of 39,240 protein-protein interactions were downloaded from HPRD. Duplicate
nodes and edges were removed and provenance of each interaction was saved as an
edge attribute. The resulting global interaction network consisted of 10,882 nodes and
70,385 interactions. The largest connected cluster of unique pairwise interactions
consisting of 10,642 nodes and 62,407 interactions was extracted for further analysis.
Global statistics are summarized for the network: the network diameter is 15; graph
density is 0.0011; average node degree is 11.72; average node betweenness, the number
of shortest paths via a node or edge are 16723 and 3759, respectively; closeness, or the
inverse of the number of nodes in the shortest path from one node to all other nodes
in the network, is .2454; the average shortest path length is 4.1281; and global cluster-
ing coefficient is 0.1314. Small average path length between network nodes and high
betweenness characterize the small world property of the network such that all nodes
are generally reachable by all other nodes in the network by relatively few steps.Weights and significance scoring
For each interaction network corresponding to HCC, CCA or BC data, edge weights
are estimated as a function of differential expression. Each node is mapped to anTable 1 Description of cancer expression data
GEO
accession
Reference Clinical outcome # of samples Controls





GSE7390 Desmedt 2007 Risk of early distant
breast cancer
metastasis (BC)




(good = 47, poor = 151)
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of the fold-change estimate for that symbol. Where multiple probes are associated with
a gene symbol, we choose the node with maximum differential expression. This ap-
proach was chosen rather than using p-values, as fold-change measures were more ro-
bust weight factors with a more discrete range of values and stable dispersion. Absolute
fold change was used in lieu of correlation values to support a semi-supervised analysis
of the association between the cumulative activity of all nodes in the module and the
outcome variables versus unsupervised clustering.
Weights are applied to each edge by calculating the square of the mean of the two
adjacent nodes of the edge, FC1j jþ FC2j j2
 
. The average weighting scheme was considered
best suited to the random walk approach as it allows for more descriptive probabilities
than weighting schemes that use for example, maximum or minimum values. Further,
this weighting scheme improves community cohesiveness in settings where and indirect
interaction may exhibit significant differential expression, but the intermediate inter-
action is non-significant.
The cumulative activity of a module is a squared transformation of the average
weighted expression for all nodes in the module; where the weight of a given node is
the maximum fold change of probes corresponding to its gene symbol. We evaluate the
significance of the magnitude of expression for modules greater than three nodes by
comparing the cumulative activity of the module against a random distribution. The
random distribution is a sample 5000 permutations of cumulative activity estimates per
module size with n nodes, and each permutation is generated by a random sampling of
n fold-change values. The module score is a test statistic comparing the cumulative
activity of a module against the bootstrap distribution ((μ0
2-μ1
2/)σerr
2), and is used to
rank high-scoring modules.Community analysis
Among graph-based approaches, the random walk on graphs performs well in defining
distances between nodes and has been applied to find communities in networks. We
utilize a random walk algorithm, Walktrap, developed by Pons and Latapy [32] and
implemented in iGraph, [44] to simulate a random walk in the interaction network.
The random walk, compared to other popular hierarchical or seed clustering methods,
utilizes the structure of the network to build distance metrics, and Walktrap optimizes
the community search using the graph-theoretic concept of modularity. The algorithm
has shown high efficiency and accuracy in revealing community structure in large net-
works [45]. The complexity of the algorithm is generally Ο(mH log n), and Ο(n3) in
sparse matrices [32] and run time statistics using the Walktrap are summarized in
Additional file 1. Further, in benchmark testing, we found the random walk to be com-
putationally more efficient than using edge-betweenness, spectral methods, or spanning
trees, to detect communities.
The algorithm begins with graph G and its associated adjacency matrix A. In the
weighted network, Aij ∈R if i and j are connected in G, and Aij = 0 otherwise. The ran-
dom walk process starts at a vertex i, and at each time point in the walk of length t, a
random step is taken to an adjacent node j. Here we set t to 3. The transition probabil-
ity at each step is Pij ¼ Aijd ið Þ where d(i) is the degree of vertex i , d(i) = ∑ jAij. Transition
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mine the probability Ptij that the walker will traverse from i to j over time t. Structural
similarity between vertices and communities are calculated using probabilities Ptij to























Where Pt measures the probability of traversing from a node in Cj to node k (j = 1,2).cjk
At each step in the merge algorithm, two communities are selected to be merged if the








After the merge step, the decrease in squared distances Δσ between the communitiesis found by:
Δσ C1−C2ð Þ ¼ 1n
C1j j C2j j
C1j j þ C2j j r
2
C1C2 ð4Þ
The merge process continues until the modularity of the network is maximized.
Modularity Q of partition R compares the fraction of edges eC inside the community C
and the fraction of edges bound to the community, aC :




Further background and details of the Walktrap implementation are provided in theoriginal work [32].
To customize the algorithm to discover significant and interpretable cancer-
associated modules in Walktrap-GM, we implement stopping criteria to search for the
optimal number of merge steps. The merge process is complete when one of the
following conditions is met: 1) maximum modularity, 2) maximum size, or 3) maximum
module score (Section Weights and significance scoring). We chose a maximum size of
200 nodes as the upper bound to maintain interpretability of modules, as we tested a sub-
set of larger maximum sizes between 200 and 500 that generally resulted in modules that
were too general in their functional annotation and therefore not as informative.
Functional annotation and overlap with GSEA
Functional annotation for significant modules is assessed using ConsensusPathDB [46]. For
top-scoring modules, we queried the list of genes in the module using overrepresentation
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WikiPathways [47], PID [48], HumanCyc [49] and Reactome [50]. Parameters include a
minimum overlap of two genes with our input gene list and the consensus pathway and
the default significance threshold, p < = .01.
We analyze each cancer phenotype using GSEA to generate a list of enriched genes.
Briefly, GSEA is a commonly applied method that searches for enrichment of highly
expressed genes in curated or custom gene sets to identify differential activity of a
priori defined gene sets in two phenotypes. The method ranks significant genes and
calculates an enrichment score for each gene set based on a weighted Kolmogorov-
Smirnov-like statistic. We apply GSEA using all canonical pathways (c3.cpv2.5) in the
Molecular Signatures Database, with the following parameters: number of permuta-
tions = 1000, collapse to gene symbols = TRUE, and permutations by phenotype. We
assess results comparing disease versus normal in HCC and CCA and high risk versus
low risk in BC. Enriched gene sets are ranked by normalized enrichment score (NES).
Overlap of top-scoring modules with results with GSEA results was evaluated by
cross-validating the top 10 GSEA gene sets ranked by NES with significantly overrepre-
sented pathways in our modules (as determined by analysis of functional annotation
using ConsensusPathDB). To evaluate the agreement of the annotation of top-scoring
modules using Walktrap-GM and GSEA, we reviewed the annotation of top-scoring
modules for overrepresentation of the top 10 gene sets ranked by NES. We report
modules that show the highest overlap with these gene sets.
Comparison with related graph-clustering platforms
The performance of Walktrap-GM is compared with two highly cited platforms devel-
oped to find network modules using gene expression data in interaction networks,
jActiveModules [20] and Matisse [22]. jActiveModules initiates module generation with
seed genes and builds a high scoring subgraph by iteratively evaluating the addition of
neighboring nodes based on their p-values. The annealing algorithm uses a temperature
parameter simulating a cooling factor that imposes a probability to the addition of
nodes that do not improve the module score and this probability decreases with each
iteration until the algorithm becomes greedy. An activity score for the modules is
calculated based on significance values associated with the proteins in the subnetwork.
Matisse applies a seed clustering algorithm that uses optimization of seed data and
similarity across expression profiles to cluster nodes. The algorithm uses high-scoring
sets of similarly expressed nodes as seed data and iteratively improves sets of seed
genes by considering the addition of connected nodes and improvement in module
score. Module scores are based on the aggregate differential activity of the subnetwork.
To evaluate the ability of these tools to identify cancer-related genes and interactions,
a list of cancer-related genes was extracted from OMIM, using text string matching
and manual curation. We queried 6995 gene references including all genes in the
clusters assessed, for cancer-related terms. The resulting list consisted of 1239 cancer-
associated genes (Additional file 2). Each matching record was reviewed to confirm that
the gene was a tumor suppressor, oncogene, or shown to be otherwise significantly
associated with cancer (i.e., by differential expression data, functional pathway analysis,
genomic mapping or SNP studies). Approximately 5% of genes did not have corre-
sponding records in OMIM and were labeled non-cancer due to lack of evidence.
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overlap = 0, and number of modules =1000. Parameters set for Matisse were beta = .95,
min seed size =2, min module size = 2, max module size =200, search strategy = all
neighbors, and no regulation priors. Walktrap modules do not include overlapping
nodes; jActiveModules was configured to not allow overlap, while the Matisse algorithm
is designed to include overlap. To evaluate the significance of each module, genes in
the interaction network were randomly sampled to generate 5000 random distributions
of class labels for each module size. The performance of each platform is assessed by
calculating a cancer-enrichment score for highly-ranked modules, or the significance of
the number known cancer genes in each module compared to the random distribution.
We also summarize the module size of significant and non-significant modules across
platforms.Results and discussion
Functional annotation
Functional annotation for significant modules is determined using ConsensusPathDB
[46]. We query genes in the top-scoring modules for overrepresentation in curated
pathways. Canonical cancer pathways and pathways associated with hallmarks of cancer
are enriched in each cancer dataset: cell-cycle control, DNA replication/repair, cellular
adhesion/migration, apoptosis, angiogenesis, evasion of the immune response and
immortality. A summary of the statistics and representative pathways for the top-
scoring modules is presented in Table 2. BC modules are highly enriched with cell cycle
control, growth signaling, focal adhesion, and angiogenesis control genes. A number of
BC modules are also annotated with progesterone, estrogen and steroid hormone
signaling; and levels of these hormones are known to correlate with BC risk. In HCC,
detoxifying pathways including cytochrome P450, UBR, HSD detoxifying pathways and
fatty acid metabolism, are among the most enriched pathways. Inflammation and
deregulation of liver-related detoxifying pathways are frequent markers of carcinogenic
toxicity, oxidative stress, and tumorigenesis. Chronic inflammation and the immune
response are associated with adenoma formation in the colon; and several related path-
ways are over-represented in CCA, including chemokine, cytokine, T-cell receptor, fatty
acid metabolism, and intestinal immunity. Wnt signaling is a key pathway in early
stages of colorectal cancer and is enriched in CCA modules. Amino acid synthesis and
metabolism pathways, associated with stability of DNA replication and repair, are over-
represented across all three cancer types, although most notably in HCC.Breast cancer
BC fold-change measurements were filtered below an FDR-adjusted p-value of .01 and
data associated with the remaining 2074 probes were used to weigh the network. The
merge process reached a maximum size at step 2069, and the community search
resulted in 8116 singletons, 206 pairs, 77 triplets and 174 modules (module size
(3 > size ≤ 200).
We examined the top-scoring modules in more detail by reviewing functional anno-
tation and referring to visualizations of the modules (Table 2, Additional file 3). These
modules were investigated to identify candidate genes, interactions with known cancer
Table 2 Functional overview of top scoring modules
Breast cancer
ID Score Size Key functional annotation
134 40.20 16 DNA REPLICATION, ATR SIGNALING, CELL CYCLE, SYNTHESIS OF DNA, UNWINDING OF DNA
82 27.77 32 VEGF AND VEGFR SIGNALING, FOCAL ADHESION, CYTOKINE RECEPTOR INTERACTIONS,
MTOR SIGNALING, PI3K CASCADE, ERBB SIGNALING, IRS SIGNALING, ANGIOGENESIS, FGFR
SIGNALING, GLYPICAN1 NETWORK, SYNDECAN SIGNALING, IGF1 PATHWAY, ARF6 SIGNALING
226 21.26 16 NUCLEAR ESTROGEN RECEPTOR ALPHA NETWORK, REGULATION OF ANDROGEN RECEPTOR
224 19.08 27 METABOLISM OF NUCLEOTIDES, DNA REPLICATION, APOPTOSIS PATHWAY, ARF6 PATHWAY,
CAM PATHWAY, TELOMERES EXTENSTION, PLC-G1 SIGNALING, GLUCAGON SIGNALING,
C-MYC TRANSCRIPTION, GNRH SIGNALING, ERBB2 SIGNALING, EGFR SIGNALING IN CANCER
79 16.08 24 JAK-STAT SIGNALING, INTERFERON SIGNALING, CYTOKINE SIGNALING, GROWTH HORMONE
RECEPTOR SIGNALING, LEPTIN SIGNALING, INSULIN SIGNALING, PROLACTIN SIGNALING,
SIGNALING BY INTERLEUKINS, SHP2 SIGNALING, ERBB2 IN SIGNAL TRANSDUCTION AND
ONCOLOGY, EPO SIGNALING, CD40/CD40L SIGNALING, EGFR SIGNALING, KIT SIGNALING
395 15.32 29 G ALPHA SIGNALING, GPCR SIGNALING, METABOLISM OF NUCLEOTIDES, CAM PATHWAY,
SIGNALING BY ERBB2, SIGNALING BY EGFR IN CANCER, GROWTH FACTOR SIGNALING
182 14.59 12 FOXM1 TRANSCRIPTION, PROGESTERONE-MEDIATED OOCYTE MATURATION,
96 13.74 13 REELIN SIGNALING, GLYCOGEN METABOLISM, SIGNALING BY INTERLEUKINS, WNT
SIGNALING, PHOSPHOINOSITIDE TARGETS, IFN-GAMMA PATHWAY, REGULATION OF
MICROTUBULE CYTOSKELETON, TGF-BETA SIGNALING, KIT SIGNALING, SEMAPHORIN
INTERACTIONS
321 10.99 5 VITAMIN A AND CAROTENOID METABOLISM, CYTOCHROME P450
145 10.97 11 CELL CYCLE, DNA DAMAGE RESPONSE, P53 SIGNALING, P38 MAPK SIGNALING, SONIC
HEDGEHOG RECEPTOR, EFP CONTROLS CELL CYCLE AND BREAST TUMORS GROWTH, TGF
BETA SIGNALING, INTEGRATED BREAST CANCER PATHWAY, MAPK SIGNALING, FOXM1
TRANSCRIPTION, AMPK SIGNALING
165 10.90 55 NUCLEAR ESTROGEN RECEPTOR NETWORK, ATF-2 TRANSCRIPTION, RETINOIC ACID
RECEPTORS-MEDIATED SIGNALING, SIGNALING MEDIATED BY P38-ALPHA AND P38-BETA,
FOXA1 TRANSCRIPTION
122 9.28 16 BCR SIGNALING, TCR SIGNALING, NATURAL KILLER CELL CYTOTOXICITY, FC EPSILON
SIGNALING, PI3K SIGNALING, JNK SIGNALING, NF-KAPPA B SIGNALING, INTERLEUKIN
SIGNALING, EPO SIGNALING, CDC42 REGULATION, EGF-EGFR SIGNALING, RAC1
REGULATION, REGULATION OF RHOA
143 8.97 11 SKP2 DEGRADATION OF P27/P21, FOXM1 TRANSCRIPTION, P73 TRANSCRIPTION, PRL
SIGNALING, ATR SIGNALING, P53 PATHWAY, RB TUMOR SUPPRESSOR/CHECKPOINT, EFP
CONTROLS CELL CYCLE/ BREAST TUMOR GROWTH, AKT SIGNALING, AHR PATHWAY, NOTCH
SIGNALING, ERBB SIGNALING, PI3K CASCADE, AMPK SIGNALING, C-MYC TRANSCRIPTIONAL
REPRESSION, SMAD2/3 SIGNALING
205 8.71 15 DNA DAMAGE RESPONSE, CELL CYCLE, INTEGRATED BREAST CANCER PATHWAY, WNT
SIGNALING, AURORA A SIGNALING, LKB1 SIGNALING, C-MYC TRANSCRIPTION REGULATION,
BARD1 SIGNALING, ATM PATHWAY, PLK3 SIGNALING, HEDGEHOG SIGNALING, ERBB
SIGNALING, P53 PATHWAY, HTERT TRANSCRIPTIONAL REGULATION, VEGFR1/ VEGFR2
SIGNALING, AP-1 TRANSCRIPTION, E2F TRANSCRIPTION, BRCA1 BRCA2 AND ATR IN CANCER,
ARF INHIBITS BIOGENESIS, NUCLEAR ESTROGEN RECEPTOR ALPHA NETWORK, AMPK
SIGNALING
89 8.54 7 REGULATION OF IGF ACTIVITY BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS
189 8.25 7 C-MYB TRANSCRIPTION, TRANSCRIPTIONAL MISREGULATION IN CANCER, AP-1 TRANSCRIPTION
348 8.20 29 REGULATION OF ACTIN CYTOSKELETON, SHC CASCADE, FGFR SIGNALING, MAPK SIGNALING,
PHOSPHOLIPASE C CASCADE, PI3K CASCADE, IRS SIGNALING, INSULIN SIGNALING,
SYNDECAN SIGNALING, ERBB SIGNALING, FOCAL ADHESION, ANGIOGENESIS
173 8.18 6 METABOLISM OF NUCLEOTIDES, DRUG METABOLISM, E2F TRANSCRIPTION
99 7.47 7 P38 SIGNALING MEDIATED BY MAPKAP KINASES, CELL CYCLE, INSULIN-MEDIATED GLUCOSE
TRANSPORT, PI3K SIGNALING MEDIATED BY AKT, INTEGRIN SIGNALING, MTOR SIGNALING,
BETA CATENIN SIGNALING, ERBB1 SIGNALING, PDGFR-BETA SIGNALING, SIGNALING BY
HIPPO
12 7.25 23 MAPK SIGNALING, ATF-2 TRANSCRIPTION, REGULATION OF P38-ALPHA AND P38-BETA, TOLL
LIKE RECEPTOR CASCADE, ERBB1 SIGNALING, NGF SIGNALING, RAS SIGNALING
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Table 2 Functional overview of top scoring modules (Continued)
Hepatocellular carcinoma
408 72.64 24 DRUG METABOLISM - CYTOCHROME P450, METABOLISM OF AMINO ACIDS, FATTY ACID
METABOLISM GLYCOLYSIS/GLUCONEOGENESIS, ETHANOL OXIDATION, ARACHIDONIC ACID
METABOLISM, TAMOXIFEN METABOLISM, VITAMIN A/CAROTENOID METABOLISM, ESTROGEN
METABOLISM, AHR PATHWAY
10 34.22 49 DRUG METABOLISM, STEROID HORMONE BIOSYNTHESIS, RETINOL METABOLISM,
CYTOCHROME P450 METABOLISM, METABOLISM OF AMINO ACIDS, TAMOXIFEN
METABOLISM, FATTY ACID OXIDATION, BENZO(A)PYRENE METABOLISM, AHR PATHWAY,
AFLATOXIN B1 METABOLISM, IL-10 SIGNALING
513 22.92 4 ALTERNATIVE COMPLEMENT PATHWAY, COMPLEMENT AND COAGULATION CASCADES
579 19.55 13 METABOLISM OF STEROID HORMONES AND VITAMINS A AND D, METABOLISM OF LIPIDS
AND LIPOPROTEINS, MINERALOCORTICOID BIOSYNTHESIS, GLUCOCORTICOID METABOLISM
603 17.58 6 METABOLISM OF AMINO ACIDS
31 14.24 14 PPAR SIGNALING, FATTY ACID, TRIACYLGLYCEROL, AND KETONE BODY METABOLISM,
ADIPOCYTOKINE SIGNALING, METABOLISM OF LIPIDS AND LIPOPROTEINS, AMPK SIGNALING
97 13.93 5 ONE CARBON POOL BY FOLATE, METABOLISM OF AMINO ACIDS AND DERIVATIVES
361 9.55 16 DNA REPLICATION, CELL CYCLE, UNWINDING OF DNA, SYNTHESIS OF DNA
314 9.47 10 FATTY ACID METABOLISM, GLYCEROLIPID METABOLISM, METABOLISM OF AMINO ACIDS
34 9.08 14 TOLL-LIKE RECEPTOR SIGNALING, HTLV-I INFECTION, ACTIVATION OF AP-1 TRANSCRIPTION
FACTORS, MAPK SIGNALING, TWEAK SIGNALING, TGF BETA SIGNALING, INTERLEUKIN
SIGNALING, RIG-I-LIKE RECEPTOR SIGNALING, HEPATITIS B VIRUS, IGF-1 SIGNALING,
HEPATOCYTE GROWTH FACTOR RECEPTOR SIGNALING, JAK-STAT SIGNALING, FAS PATHWAY
598 8.94 4 KEAP1-NRF2 PATHWAY, METABOLISM OF AMINO ACIDS AND DERIVATIVES
360 8.73 7 INSULIN SIGNALING, GLYCOGEN METABOLISM, GLUCOSE METABOLISM, METABOLISM OF
CARBOHYDRATES
112 8.65 5 MRNA SPLICING, MRNA PROCESSING
515 8.46 10 ONE CARBON POOL BY FOLATE, FOLATE METABOLISM
257 8.23 5 UREA CYCLE AND METABOLISM OF AMINO GROUPS, METABOLISM OF AMINO ACIDS
153 7.29 5 GLUCOCORTICOID & MINERALCORTICOID METABOLISM, METABOLISM OF STEROID
HORMONES & VITA/D, METABOLISM OF LIPIDS & LIPOPROTEINS, PROSTAGLANDIN
SYNTHESIS/ REGULATION
123 7.22 7 ONE CARBON FOLATE METABOLISM, METHYLATION, METABOLISM OF AMINO ACIDS
254 7.03 6 METABOLISM OF NUCLEOTIDES, METABOLISM OF AMINO ACIDS AND DERIVATIVES
429 7.02 9 SIGNAL TRANSDUCTION BY L1, MTOR SIGNALING, RSK ACTIVATION, PROSTATE CANCER,
L1CAM INTERACTIONS, CREB PHOSPHORYLATION THROUGH THE ACTIVATION OF RAS,
MAPK SIGNALING
414 6.50 35 MAPK SIGNALING, ATF-2 TRANSCRIPTION, CELL SIGNALING IN H. PYLORI INFECTION,
ACTIVATION OF AP-1 TRANSCRIPTION FACTORS, FC EPSILON RI SIGNALING, NOD1/2
SIGNALING, GNRH SIGNALING, JNK SIGNALING, CD40/CD40L SIGNALING, C RIG-I-LIKE
RECEPTOR SIGNALING, TGF BETA SIGNALING, VEGF SIGNALING, EGF-EGFR SIGNALING, FOSB
GENE EXPRESSION
Colorectal adenoma
257 33.48 50 CHEMOKINE SIGNALING, GPCR SIGNALING, NF-KAPPA B SIGNALING, CXCR3 SIGNALING,
TOLL-LIKE RECEPTOR SIGNALING, NOD-LIKE RECEPTOR SIGNALING, INTESTINAL IMMUNE
NETWORK FOR IGA PRODUCTION, INTERLEUKIN SIGNALING, CELL SIGNALING IN H. PYLORI
INFECTION
182 21.57 25 TIGHT JUNCTION INTERACTIONS, TRANSENDOTHELIAL MIGRATION, CELL-CELL
COMMUNICATION, CAMS
158 18.94 9 P75(NTR) SIGNALING, DEGRADATION OF THE ECM, ECM ORGANIZATION, SYNDECAN SIGNALING
770 12.58 8 ETHANOL OXIDATION, METABOLISM BY CYTOCHROME P450, TYROSINE METABOLISM, FATTY
ACID METABOLISM, GLYCOLYSIS/GLUCONEOGENESIS, VITAMIN A/CAROTENOID METABOLISM
14 11.51 5 C-MYC TRANSCRIPTIONAL REPRESSION, SMAD2/3 SIGNALING, CELL CYCLE, PATHWAYS
IN CANCER
452 8.75 10 GLYCOSPHINGOLIPID BIOSYNTHESIS, GLYCOSAMINOGLYCAN BIOSYNTHESIS
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Table 2 Functional overview of top scoring modules (Continued)
487 7.16 28 MAPK SIGNALING, ATF-2 TRANSCRIPTION, ACTIVATION OF AP-1 TRANSCRIPTION FACTORS,
NOD-LIKE RECEPTOR SIGNALING, FC EPSILON SIGNALING, GNRH SIGNALING, TOLL-LIKE
RECEPTOR SIGNALING, INTERLEUKIN SIGNALING, TGF BETA SIGNALING, VEGF SIGNALING,
EGF-EGFR SIGNALING, KIT SIGNALING, RANKL-RANK SIGNALING, COLORECTAL CANCER, S1P2
PATHWAY, NONCANONICAL WNT SIGNALING, ARF6 PATHWAY, ERBB SIGNALING, TBXA2R
SIGNALING
301 7.06 7 TRANSCRIPTIONAL MISREGULATION IN CANCER, RB REGULATION, INTERLEUKIN SIGNALING,
C-MYB TRANSCRIPTION, INTERFERON SIGNALING, FOXA2/ FOXA3 TRANSCRIPTIONS, SMAD2/
3 SIGNALING
758 6.91 5 METABOLISM OF AMINO ACIDS AND DERIVATIVES
762 6.59 12 WNT SIGNALING, SECRETIN FAMILY OF RECEPTORS, HTLV-I INFECTION, SIGNALING BY GPCR
240 6.59 28 G PROTEIN SIGNALING, CAM PATHWAY, PLC-GAMMA1 SIGNALING, NUCLEOTIDE
METABOLISM, SIGNALING BY ERBB2, SIGNALING BY EGFR, SIGNALING BY FGFR, SIGNALING
BY PDGF
757 6.53 12 METABOLISM OF STEROID HORMONES AND VITA/D, METABOLISM OF LIPIDS AND
LIPOPROTEINS, GLUCOCORTICOID & MINERALCORTICOID METABOLISM, BILE ACID AND BILE
SALT METABOLISM
410 6.49 6 JAK-STAT SIGNALING, CYTOKINE-CYTOKINE RECEPTOR INTERACTION, SHP2 SIGNALING,
INTERLEUKIN SIGNALING, ROLE OF ERBB2 IN SIGNAL TRANSDUCTION AND ONCOLOGY
412 6.21 9 DNA REPLICATION, CELL CYCLE, UNWINDING OF DNA, ATR SIGNALING, E2F TRANSCRIPTION
345 6.13 14 NEUROTROPHIN SIGNALING, GNRH SIGNALING, CREB PHOSPHORYLATION, PKA ACTIVATION,
CAM PATHWAY, INSULIN SIGNALING, PGC-1A REGULATION, RAS REGULATION, SMAD2/3
SIGNALING
267 6.06 6 METABOLISM OF PROTEINS
334 6.04 12 BETA-CATENIN PHOSPHORYLATION CASCADE, SIGNALING BY WNT, GLYCOGEN METABOLISM,
PLATELET HOMEOSTASIS, DNA REPLICATION, CELL CYCLE, DNA DAMAGE RESPONSE
111 5.74 11 ECM-RECEPTOR INTERACTION, FOCAL ADHESION, INTEGRIN INTERACTIONS, NCAM
INTERACTIONS, SYNDECAN SIGNALING, PROTHROMBIN ACTIVATION PATHWAY, PDGF
SIGNALING, VEGFR3 SIGNALING
54 5.73 4 NONE
125 5.67 20 CHEMOKINE SIGNALING, G ALPHA SIGNALING, SIGNALING BY GPCR, ACTIVATION OF PKA,
INTESTINAL IMMUNE NETWORK FOR IGA, CELL SIGNALING IN HELICOBACTER PYLORI INFECTION
183 5.41 6 BETA-CATENIN PHOSPHORYLATION CASCADE, CTLA4 INHIBITORY SIGNALING, GLYCOGEN
METABOLISM, WNT SIGNALING, DNA REPLICATION, CELL CYCLE, IMMUNE SYSTEM, DNA
DAMAGE RESPONSE
156 5.38 4 HEMATOPOIETIC CELL LINEAGE
144 5.35 16 CELL CYCLE, P38/MAPKAP SIGNALING, LKB1 SIGNALING, INSULIN-MEDIATED GLUCOSE
TRANSPORT, PI3K/AKT SIGNALING, INTEGRIN SIGNALING, FOXO FAMILY SIGNALING, MTOR
SIGNALING, ERBB1 SIGNALING, PDGFR-BETA SIGNALING, ATR SIGNALING, PLK1 SIGNALING, RB
TUMOR SUPPRESSOR/CHECKPOINT, RAP1 SIGNALING, INTEGRATED CANCER PATHWAY, ATM
PATHWAY, SHC SIGNALING, ARMS-MEDIATED ACTIVATION, IGF1 PATHWAY, IRS SIGNALING
Petrochilos et al. BioData Mining 2013, 6:17 Page 12 of 25
http://www.biodatamining.org/content/6/1/17genes, and interactions between pathways. Among these top modules, we found highly
differentially expressed candidate genes and relevant cancer interactions in modules
143, 79 and 82 (Figure 2). Module 143 is composed of cyclins regulating the cell cycle
and a link to telomere formation (E2F5). SKP2 is a known oncogene and interacts with
cyclins to promote cell proliferation and evade apoptosis [51]. SKP2 and cyclin CCNA2
show significantly altered activity and interact with G2-phase cell cycle checkpoint
genes BRCA2 via CDK2. Module 79 involves interactions between cytokines and JAK/
STAT regulation of signal transduction, cellular proliferation and differentiation.
SOCS1, SOCS2, SOCS3 and CBLC are involved in mediating JAK/STAT signaling, in the
inflammatory response and in cellular growth. Differentially expressed genes include
Figure 2 Intersection of BC modules 143, 79 and 82. Module 143, designated by square nodes, shows
interactions among cyclins, SKP2 and BRCA2. Module 79, designated by rectangular nodes shows
interactions among cytokines, SOCS genes and genes in the JAK-STAT pathway. The JAK-STAT pathway is
associated with B-cell growth and proliferation and a number of genes in this pathway are related to
cancer. Module 82, designated by circular nodes, shows interactions among the MET oncogene and critical
cancer-associated growth factors including IGF1R, PDGFRA, VEGFA, and ERBB4. Among genes in this module,
IRS2 and FGF7 are differentially regulated and may be interesting targets for further research. Red nodes
designate cancer-associated genes based on descriptions in OMIM. Node sizes correspond to the absolute
values of the fold change of differentially regulated genes (up- or down-regulated). Blue edges are derived
from HPRD, green from KEGG, and orange from both databases.
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http://www.biodatamining.org/content/6/1/17SOC2, SOC3, CBLC, and the interleukin receptor IL20RA; and the altered expression
and coordinated interaction and of these genes suggest a concerted role in BC progres-
sion. Module 82 shows interaction between a number of growth factors and receptors,
including FIGF, IGFIR, PDGFRA, EGFR, the MET oncogene, and tumor regulator
ERBB4. The oncogene MET interacts with several growth factors, including FGF7,
which mediates epithelial proliferation and has a potential role in gastric cancer
[52]. VEGFA is a known metastatic vascular growth marker and a therapeutic
target for breast cancer survival. IRS2 affects proliferation and regeneration of cells,
expression of this gene is critical during development and growth, and the gene
may influence cancer survival [53,54]. IRS2 and FGF7 represent interesting candi-
date disease genes given their key functions and clinical relevance in aberrant
cellular growth and proliferation.
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HCC data included 16,360 probes after filtering by p-value. The maximal score was
reached at 2393 steps, resulting in 7666 singletons, 352 pairs, 128 triplets, and 198
modules. At this step size, the maximum module size was 54 (module size (3 > size ≤ 54).
The top-scoring modules are summarized in Table 2 and Additional file 4. We
reviewed highly expressed candidate genes and interactions modules 361, 429 and 414
in greater detail. Module 361 (Figure 3) consists of interactions between a family of
cyclins, origin recognition complexes, and minchromosome maintenance genes. Kinase
activation of CDC7 is dependent on expression of DBF4, and both genes are highly
expressed in cancer [55]. MCM5 forms a complex with MCM2 [56], a candidate
oncogene phosphorylated by CDC7. ORC5L associates with CDC7 and MCM5 in
the network and this group of genes display altered expression in HCC tissue.
These genes exhibit high differential expression and have implications in tumor
formation due to their role in regulating the cell-cycle and cellular proliferation.Figure 3 HCC module 361. Module 361 shows interactions among MCM, ORC genes involved in cell-cycle
control, and DBF4. A number of MCM genes are known to be involved in cancer, and DBF4 appears to play
an interesting role in the cell cycle via interactions presented in this network and with other critical cell-
cylce control genes. Red nodes designate cancer-associated genes based on descriptions in OMIM. Node
sizes correspond to the absolute values of the fold change of differentially regulated genes (up- or down-
regulated). Blue edges are derived from HPRD.
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alter cancer risk [57], and interaction with the oncogene NOV, and transcription
factors RPS6KA2 and RPS6KA6. These transcription factors are associated with the
RSK family of genes, involved in activating map kinase growth signaling, cell cycle
control and differentiation. Given their importance in cellular development, their
potential implication in cancer [58,59] and association with IGFI and NOV, these
RSK transcription factors are compelling candidate cancer genes. Module 414
(Figure 4) shows the interaction between MAPK signaling genes, DUSP genes and
FOS and JUND oncogenes. The DUSP genes regulate the activity of MAPK signal-
ing cascades, and several map kinase targets are known to be involved in aberrant
proliferation in cancer. The kinase RIPK2 has an important function in apoptosis
and interactions with the MAPK signaling and high differential expression in this
module suggest a potential role in tumorigenesis. Due to their association with
known cancer genes and high differential expression, DUSP1, DUSP9, MAPK9 and
RIPK2 genes are promising targets for therapeutic research.Figure 4 HCC module 414. Module 414 shows interactions among MAPK, DUSP genes and FOSB and JUNB
oncogenes. The DUSP family of genes is known to regulate the activity of MAP kinases, a number of which
play a role in cancer. This module presents interactions among MAPK genes and the oncogene JUNB,
protooncogene FOSB, and RIPK2. RIPK2 is not well-described, but appears to play a role in apoptosis. Red
nodes designate cancer-associated genes based on descriptions in OMIM. Node sizes correspond to the
absolute values of the fold change of differentially regulated genes (up- or down-regulated). Blue edges are
derived from HPRD, green from KEGG, and orange from both databases.
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CCA data included 21,648 probes after filtering by p-value. The maximal score was
reached at 2967 steps. The resulting community structure included 6879 singletons,
385 pairs, 149 triplets and 253 modules. The maximum module size at this step was
160 (module size (3 > size ≤ 160).
The top-scoring modules are summarized in Table 2 and Additional file 5. We
reviewed modules 301, 144, and 762 in detail based on the differential expression of
potential cancer-associated genes and relevance of their functional annotation in
cancer. There are three known oncogenes in module 301 (Figure 5): SPI1, RUNX1, and
IRF4. CEBPB and CEBPE interact with these oncogenes, affect cellular proliferation,
and alter tumor development and cancer risk [60,61]. Transcription factors SPI1and
RUNX1 participate in hematopoietic stem cell formation and can lead to the develop-
ment of multiple cell lineages in cancer [62,63]. These genes show altered expression in
the network, and specifically, the role of the highly differentially regulated transcription
factor SPIB in colorectal cancer is an interesting area for further research. Module 144
(Figure 6) shows interactions between CDK1, a key regulator of the cell cycle andFigure 5 CCA module 301. Module 301 shows interactions among cancer-related transcription factors.
The role of SPIB in cancer is of interest is as this transcription factor is highly differentially regulated in this
module and interacts closely with known cancer genes. Node sizes correspond to the absolute values of
the fold change of differentially regulated genes (up- or down-regulated). Blue edges are derived from
HPRD, green from KEGG, and orange from both databases.
Figure 6 CCA module 144. Module 144 shows interactions among cell cycle regulatory genes and FOXM1
oncogene. WEE1, CDC25C, YWHAE and BRSK1 are also involved in cell cycle control and interact closely with
cancer-associated genes, but are not themselves well-described as cancer genes. Also of note, WEE1 and
CDC25C are known to play an antagonistic role in regulating the cell cycle. Red nodes designate cancer-
associated genes based on descriptions in OMIM. Node sizes correspond to the absolute values of the fold
change of differentially regulated genes (up- or down-regulated). Blue edges are derived from HPRD, green
from KEGG, and orange from both databases.
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HMGA2, and FOXM1. Putative candidates among neighboring genes include
BRSK1, WEE1, and CDC25C, which are involved in cell-cycle checkpoints and are
overexpressed in CCA. Specifically, WEE1 and CDC25C are significantly differen-
tially regulated and are known to play a mutually antagonistic role in cell-cycle
control. BRSK1 is not well described, but exhibits key interactions with genes
involved in cell-cycle control. Module 762 (Additional file 5) consists of interac-
tions among SFRP1 and SFRP2 genes and FZD genes in the Wnt pathway. The
Wnt pathway is involved in cell polarity and malignant cell transformation in
colorectal cancer, and the SFRP1 and SFRP2 [64] genes interfere with normal Wnt
signaling. SFRP genes and most frizzled FZD genes in the module show altered
expression. Given the topology of SFRP1 and SFRP2 as hubs in this module, these
genes appear to play a central role the Wnt pathway and CCA development.
Descriptions of genes highlighted in BC, HCC and CCA modules are summarized
in Additional file 6.
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We analyzed BC, HCC and CCA data using GSEA and canonical pathways in MSigDB.
The overlap of top-scoring Walktrap-GM annotation with GSEA results was evaluated
by cross-validating the top 10 GSEA pathways with pathways significantly overrepre-
sented in our dataset (p ≤ .01). Notably in the BC data, module 205 overlaps with the
following highest-ranking GSEA pathways, Cell Cycle (p = 1.56 × 10-08), Ubiquitin-
mediated Proteolysis (p = 7.66 × 10-05), DNA Replication (p = .0085), G1-S Phase
(p = 4.23 × 10-08), the ATR-BRCA pathway (p = .0005), and Apoptosis (p = .0074). Module
224 exhibits significant overrepresentation in Pyrimidine Metabolism (p = 1.37 × 10-24)
Apoptosis (p = 3.08 × 10-06) and DNA Replication (p = 7.43 × 10 -05) pathways which are
among the top 10 enriched pathways in GSEA.
HCC module 408 shows significant enrichment with the 10 highest-ranking GSEA
results, including Tryptophan (p = 6.89 × 10-08), Tyrosine (p = 2.92 × 10-29), Beta-
Alanine (p = 6.05 × 10-07), and Arachidonic Acid (p = 2.15 × 10-14) metabolism. Signifi-
cant pathways overrepresented in Module 314 that overlap with the top GSEA modules
are Tryptophan (p = 6.10 × 10-13), Propanoate (p = 6.34 × 10-11), Tyrosine (p = .0007),
Beta-Alanine (p = 8.43 × 10-20), Valine, Leucine and Isoleucine (p = 3.40 × 10-10), Lysine
(1.94 × 10-12), Phenylalanine (.0001), and Glycerolipid (9.86 × 10-10) metabolism.
In CCA, module 144 overlaps with the top 10 ranked pathways in GSEA, including
the ATM (p = 1.78 × 10-05), Cell Cycle (p = 9.92 × 10-19), P53 (p = .0046), and
ATR (p = 2.1 × 10-07) pathways, and module 412 shows overlap with the Cell
Cycle (p = 8.58 × 10-16) and G1 to S Phase (p = 6.91 × 10-21). Overall, the consistency
observed with GSEA suggests that processes similar to those highlighted by GSEA are
also detected by highly-rankedWalktrap-GM network modules.
Comparison with related graph-clustering platforms
Properties of Walktrap-GM are compared to those of several other approaches in
Table 3, including heuristics for clustering, learning methods and parameter tuning.
Compared with MCL [65], Affinity-Propagation [66], and Netwalker [31] that use
similarity values to cluster nodes, Walktrap-GM clustering can be implemented using
similarity or significance values, here we use significance scores to perform a supervised
search for modules that are associated with the phenotype of interest. The Matisse
algorithm clusters by similarity, using the iterative addition of significant seed genes to
find optimal scoring modules. jActiveModules uses differential expression to build
subnetworks; however, the platform is restricted to using only p-values. Among these
approaches, Walktrap-GM allows for semi-supervised learning of non-overlapping
modules using significant differential expression as edge weights.
We evaluate the performance of Walktrap-GM with two platforms widely used to
find network modules using gene expression data in interaction networks,
jActiveModules [20] and Matisse [22]. Results are summarized in Figure 7. Walktrap-
GM generally performed as well or better than Matisse or jActiveModules using the
HCC and CCA data and performs consistently well overall. Matisse modules include
overlap, so the corresponding set of top modules display greater coverage of significant
interactions, but redundant sets of significant genes. By excluding overlapping genes,
Walktrap-GM focuses the search for unique interactions across modules. We also
consider module size; distribution of module sizes for each dataset and platform are
Table 3 Comparison of approaches to module-finding in biological networks





Walktrap-BM Random walk Differential expression or pairwise
similarity
Semi-supervised No Modularity, size, score Yes R on Unix, Windows, Mac
jActiveModules [20,21] Simulated annealing Differential expression (P-values only) Semi-supervised Optional K-modules, number of paths,
iterations
Yes Cytoscape plugin on
Windows, Mac, Linux
Matisse [22] Seed clustering Pairwise similarity and significant
seed nodes
Semi-supervised Yes Module size, seed number Yes Linux, Windows
NetWalker [23,31] Random walk Differential expression Unsupervised Optional K-Modules Yes Windows, Mac
Affinity Propagation [66] Seed-based message
propagation
Pairwise similarity Unsupervised Yes Preference values,
seed number
Yes Matlab, R on Windows
and Linux

















Figure 7 Comparison of top modules from Walktrap-GM, Matisse, jActiveModules. Performance in
finding modules significantly enriched with known cancer genes,across breast cancer (BC) and
hepatocellular carcinoma (HCC) and colorectal cancer data (CCA). Green lines show Walktrap-GM
performance, blue jActiveModules, and orange Matisse. Walktrap-GM performs as well as or better than the
other approaches across datasets. In the BC data, blue jActiveModules resulted in one very large and
significant module of 981 nodes, but few significant modules overall. Matisse includes overlapping
significant genes within its modules where Walktrap-GM does not and jActiveModules is configured not to
inlcude overlap.
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of 981 nodes in BC and a module of 377 nodes in CCA. The majority of significant
modules generated by Matisse include more than 100 nodes. Generally, large clusters
demand further mining to discover the most relevant interactions and genes in each
module. The smaller distribution of module sizes associated with Walktrap-GM
highlights a more specific and informative set of biological interactions that facilitates
interpretation of modules; where the functional annotation of larger modules that may
otherwise be too general to be meaningful. Further, the time required to run the
Walktrap algorithm (summarized in Additional file 1) compared favorably to the other
tools, on a scale of minutes for each dataset on a 64-bit, 8 GB. 2.8 GHz, machine,
compared to several hours running jActiveModules and Matisse.Conclusions
Network analysis provides a framework to search for communities of genes associated
with disease by modeling their coordinated behavior and biological knowledge of their
interactions. We use a random walk algorithm optimized to search for communities in
Figure 8 Distribution of module sizes by score for each dataset. Walktrap-GM markers are noted in
green, Matisse in orange, and jActiveModules in blue. Walktrap-GM includes a size threshold of 200, and
identifies significant modules that are generally smaller. Smaller modules tend to have more specific and
informative functional interpretation; the functional annotation of large modules may be too general to
be meaningful.
Petrochilos et al. BioData Mining 2013, 6:17 Page 21 of 25
http://www.biodatamining.org/content/6/1/17large networks, to mine for disease genes in a weighted interaction network. The
network is weighted with differential gene expression corresponding to adenoma
development, tumor growth, and cancer progression. This approach is used to
discover cancer-associated modules in a network of biological interactions weighted
by differential gene expression of breast cancer, hepatocellular carcinoma and colo-
rectal cancer data.
Walktrap-GM identifies modules relevant to the etiology of multiple cancer out-
comes, and suggests interactions among promising candidate genes for further study of
their role in cancer or potential therapeutic intervention. Functional analysis of
modules discovered in this analysis reveals strong enrichment of cancer-related path-
ways and known cancer genes. Pathways enriched across the BC, HCC and CCA data
include those involved in cell cycle control, DNA replication, DNA damage and repair,
amino acid metabolism, inflammation, and cell adhesion and migration. Specifically,
several genes may represent targets for further research, including CBLC or IRS2, which
influence breast cancer survival; transcription factors RPS6KA2 and RPS6KA6, the
interaction among MCM/CDC and ORC cell cycle control genes, and DUSP1, DUSP9,
RIPK2 and MAPK9 in the onset of hepatocellular carcinoma; or cell-cycle genes
BRSK1, WEE1, CDC25C, and the transcription factor SPIB in colorectal adenoma
development. Significant interactions among these candidate genes can be used to
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peutic value of these targets in cancer.
This network analysis approach has potential applications to a diverse body of
biological data, for example, protein complex prediction, functional prediction, gene
variation, and regulatory interactions. Similar functional annotation or correlation
expression can be applied to the network to predict protein complexes or functional
annotation of unknown genes. SNP or eQTL data can be integrated to search for mod-
ules that demonstrate significant genetic variation in case–control data. Transcription
factor, methylation or miRNA data can be coupled with their regulatory targets to dis-
cover significant regulatory modules. Text-mining applications can highlight significant
relationships among terms by mapping the co-occurrence of their expressions in the
literature. Related edge weighting schemes may include correlation coefficients, signifi-
cance values based on association with phenotypes of interest, or confidence scores that
reflect the level of certainty corresponding to a biological interaction.
These findings show that Walktrap-GM identifies biologically relevant modules asso-
ciated with cancer and performs well compared with other module search platforms,
Matisse and jActiveModules. Strong performance combined with smaller, more specific,
and non-overlapping modules, facilitates biological interpretation of these results.
These modules reflect known pathways in cancer and present hypotheses for clinical
studies. Future work may include an analysis across additional cancer and other com-
plex disease data, or apply these methods to integrate more classes of genomic data
such as SNP, miRNA or next generation sequencing data.Availability and requirements
∎Project name: Walktrap-GM
∎Project home page: http://github.com/petrochilos/walktrap-GM.git
∎Operating system(s): platform independent
∎Programming Language: R
∎Other Requirements: recommended minimum requirements include 8 MB RAM,
2.8 GHz processor, 64-bit system
∎License: GNU GPL
Additional files
Additional file 1: Walktrap performance by Network Size and Density.
Additional file 2: List of labeled cancer genes curated from Online Mendelian Inheritance in Man
database (OMIM).
Additional file 3: Visualization of top ranked BC modules.
Additional file 4: Visualization of top ranked HCC modules.
Additional file 5: Visualization of top ranked CCA modules.
Additional file 6: Key genes described in BC, HCC and CCA modules.Abbreviations
BC: Breast cancer; HCC: Hepatocellular carcinoma; CCA: Colorectal cancer adenoma.
Competing interests
The authors have no competing interests to declare.
Petrochilos et al. BioData Mining 2013, 6:17 Page 23 of 25
http://www.biodatamining.org/content/6/1/17Authors’ contributions
DP conceived of the study and carried out data, graph, and statistical analysis. NA, AS, and JG participated in the
design of the study, including technical and statistical evaluation, and review of the manuscript. All authors read and
approved the final manuscript.Acknowledgments
We would like to thank Ira Kalet and Alexander Tsiatas for their helpful input and advice. We received funding for this
research from NLM grant 5T15LM007442-07.
Author details
1Biomedical and Health Informatics, Dept of Biomedical Informatics and Medical Education, University of Washington,
Box 357240, 1959 NE Pacific Street, HSB I-264, Seattle, WA 98195-7240, USA. 2Department of Biostatistics, University of
Washington, Box 357232, F-650 Health Sciences Bldg, Seattle, WA, USA.
Received: 17 December 2012 Accepted: 24 September 2013
Published: 15 October 2013References
1. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR,
Lander ES, Mesirov JP: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-
wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545–15550.
2. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC: A global test for groups of genes: testing
association with a clinical outcome. Bioinformatics 2004, 20(1):93–99.
3. Dinu I, Potter JD, Mueller T, Liu Q, Adewale AJ, Jhangri GS, Einecke G, Famulski KS, Halloran P, Yasui Y: Improving
gene set analysis of microarray data by SAM-GS. BMC Bioinformatics 2007, 8:242.
4. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, Olson JA Jr,
Marks JR, Dressman HK, West M, Nevins JR: Oncogenic pathway signatures in human cancers as a guide to
targeted therapies. Nature 2006, 439(7074):353–357.
5. Liu D, Ghosh D, Lin X: Estimation and testing for the effect of a genetic pathway on a disease outcome using
logistic kernel machine regression via logistic mixed models. BMC Bioinformatics 2008, 9:292.
6. Segal E, Friedman N, Koller D, Regev A: A module map showing conditional activity of expression modules in
cancer. Nat Genet 2004, 36(10):1090–1098.
7. Efroni S, Schaefer CF, Buetow KH: Identification of key processes underlying cancer phenotypes using biologic
pathway analysis. PLoS ONE 2007, 2(5):e425.
8. Shojaie A, Michailidis G: Network enrichment analysis in complex experiments. Stat Appl Genet Mol Biol 2010,
9(1):22.
9. Shojaie A, Michailidis G: Analysis of gene sets based on the underlying regulatory network. J Comput Biol 2009,
16(3):407–426.
10. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL: The human disease network. Proc Natl Acad Sci USA
2007, 104(21):8685–8690.
11. Jonsson PF, Bates PA: Global topological features of cancer proteins in the human interactome. Bioinformatics
2006, 22(18):2291–2297.
12. Petrochilos D, Abernethy N: Assessing network characteristics of cancer associated genes in metabolic and
signaling networks. In, Computational Intelligence in Bioinformatics and Computational Biology (CIBCB), 2012 IEEE
Symposium on 2012San Diego, CA:290–297.
13. Xu J, Li Y: Discovering disease-genes by topological features in human protein-protein interaction network.
Bioinformatics 2006, 22(22):2800–2805.
14. Kohler S, Bauer S, Horn D, Robinson PN: Walking the interactome for prioritization of candidate disease genes.
Am J Hum Genet 2008, 82(4):949–958.
15. Li L, Zhang K, Lee J, Cordes S, Davis DP, Tang Z: Discovering cancer genes by integrating network and
functional properties. BMC Med Genomics 2009, 2:61.
16. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS, Rennert G, Moreno V, Kirchhoff T, Gold B, Assmann
V, Elshamy WM, Rual JF, Levine D, Rozek LS, Gelman RS, Gunsalus KC, Greenberg RA, Sobhian B, Bertin N,
Venkatesan K, Ayivi-Guedehoussou N, Sole X, Hernandez P, Lazaro C, Nathanson KL, Weber BL, Cusick ME, Hill DE,
Offit K, et al: Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007,
39(11):1338–1349.
17. Nibbe RK, Koyuturk M, Chance MR: An integrative -omics approach to identify functional sub-networks in
human colorectal cancer. PLoS Comput Biol 2010, 6(1):e1000639.
18. Tu Z, Argmann C, Wong KK, Mitnaul LJ, Edwards S, Sach IC, Zhu J, Schadt EE: Integrating siRNA and protein-
protein interaction data to identify an expanded insulin signaling network. Genome Res 2009, 19:1057–1067.
19. Dittrich MT, Klau GW, Rosenwald A, Dandekar T, Muller T: Identifying functional modules in protein-protein
interaction networks: an integrated exact approach. Bioinformatics 2008, 24(13):i223–i231.
20. Ideker T, Ozier O, Schwikowski B, Siegel AF: Discovering regulatory and signalling circuits in molecular
interaction networks. Bioinformatics 2002, 18(Suppl 1):S233–S240.
21. Chuang HY, Lee E, Liu YT, Lee D, Ideker T: Network-based classification of breast cancer metastasis. Mol Syst Biol
2007, 3:140.
22. Ulitsky I, Shamir R: Identification of functional modules using network topology and high-throughput data.
BMC Syst Biol 2007, 1:8.
23. Komurov K, White MA, Ram PT: Use of data-biased random walks on graphs for the retrieval of context-
specific networks from genomic data. PLoS Comput Biol 2010, 6(8):e1000889.
Petrochilos et al. BioData Mining 2013, 6:17 Page 24 of 25
http://www.biodatamining.org/content/6/1/1724. Orman GK, Labatut V: Relative evaluation of partition algorithms for complex networks. In , Networked Digital
Technologies, 2009 NDT '09 First International Conference on 2009Ostrava, Czech Republic: IEEE:20–25.
25. Navlakha S, Kingsford C: The power of protein interaction networks for associating genes with diseases.
Bioinformatics 2010, 26(8):1057–1063.
26. Yao X, Hao H, Li Y, Li S: Modularity-based credible prediction of disease genes and detection of disease
subtypes on the phenotype-gene heterogeneous network. BMC Syst Biol 2011, 5:79-0509-5-79.
27. Li Y, Patra JC: Genome-wide inferring gene-phenotype relationship by walking on the heterogeneous
network. Bioinformatics 2010, 26(9):1219–1224.
28. Tu Z, Wang L, Arbeitman MN, Chen T, Sun F: An integrative approach for causal gene identification and gene
regulatory pathway inference. Bioinformatics 2006, 22(14):e489–e496.
29. van Dongen S, Abreu-Goodger C: Using MCL to extract clusters from networks. Methods Mol Biol 2012,
804:281–295.
30. Wu G, Stein L: A network module-based method for identifying cancer prognostic signatures. Genome Biol
2012, 13(12):R112.
31. Komurov K, Dursun S, Erdin S, Ram PT: NetWalker: a contextual network analysis tool for functional genomics.
BMC Genomics 2012, 13:282-2164-13-282.
32. Pons P, Latapy M: Computing communities in large networks using random walks. JGAA 2006, 10(2):191–218.
33. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M: KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res 1999, 27(1):29–34.
34. Peri S, Navarro JD, Amanchy R, Kristiansen TZ, Jonnalagadda CK, Surendranath V, Niranjan V, Muthusamy B, Gandhi
TK, Gronborg M, Ibarrola N, Deshpande N, Shanker K, Shivashankar HN, Rashmi BP, Ramya MA, Zhao Z, Chandrika
KN, Padma N, Harsha HC, Yatish AJ, Kavitha MP, Menezes M, Choudhury DR, Suresh S, Ghosh N, Saravana R,
Chandran S, Krishna S, Joy M, et al: Development of human protein reference database as an initial platform
for approaching systems biology in humans. Genome Res 2003, 13(10):2363–2371.
35. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R:
NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res 2005,
33(Database issue):D562–D566.
36. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX, Wang XW: A
unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular
carcinoma patients. Cancer Res 2010, 70(24):10202–10212.
37. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies
MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C:
TRANSBIG Consortium: strong time dependence of the 76-gene prognostic signature for node-negative
breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007,
13(11):3207–3214.
38. Sabates-Bellver J, Van der Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki
JM, Menigatti M, Luz J, Ranalli TV, Gomes V, Pastorelli A, Faggiani R, Anti M, Jiricny J, Clevers H, Marra G:
Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007, 5(12):1263–1275.
39. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple
testing. JSTOR 1995, 57(1):289–300.
40. Davis S, Meltzer PS: GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor.
Bioinformatics 2007, 23(14):1846–1847.
41. Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol 2004, 3:3.
42. Smyth GK: Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using
R and Bioconductor. Edited by Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. New York, NY: Springer;
2005:397.
43. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K,
Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney
L, Yang JY, Zhang J: Bioconductor: open software development for computational biology and bioinformatics.
Genome Biol 2004, 5(10):R80.
44. Csardi G, Nepusz T: The igraph software package for complex network research. InterJournal 2006, Complex
Systems:1695.
45. Rodrigues FA, de Arruda FG, da Fontoura CL: A complex networks approach for data clustering. ArXiv e-prints
2011:. arXiv:1101.5141.
46. Kamburov A, Wierling C, Lehrach H, Herwig R: ConsensusPathDB–a database for integrating human functional
interaction networks. Nucleic Acids Res 2009, 37(Database issue):D623–D628.
47. Pico AR, Kelder T, van Iersel MP, Hanspers K, Conklin BR, Evelo C: WikiPathways: pathway editing for the people.
PLoS Biol 2008, 6(7):e184.
48. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH: PID: the Pathway Interaction
Database. Nucleic Acids Res 2009, 37(Database issue):D674–D679.
49. Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, Karp PD: Computational prediction of human
metabolic pathways from the complete human genome. Genome Biol 2005, 6(1):R2.
50. Robertson M: Reactome: clear view of a starry sky. Drug Discov Today 2004, 9(16):684–685.
51. Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J, Sellers RS, Nakayama K, Nakayama KI, Cobrinik D, Zhu L: Skp2 is
required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice.
Nat Genet 2010, 42(1):83–88.
52. Shaoul R, Eliahu L, Sher I, Hamlet Y, Miselevich I, Goldshmidt O, Ron D: Elevated expression of FGF7 protein is
common in human gastric diseases. Biochem Biophys Res Commun 2006, 350(4):825–833.
53. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H, Satoh S,
Sekihara H, Sciacchitano S, Lesniak M, Aizawa S, Nagai R, Kimura S, Akanuma Y, Taylor SI, Kadowaki T: Disruption
Petrochilos et al. BioData Mining 2013, 6:17 Page 25 of 25
http://www.biodatamining.org/content/6/1/17of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of
compensatory beta-cell hyperplasia. Diabetes 2000, 49(11):1880–1889.
54. Huang SP, Bao BY, Hour TC, Huang CY, Yu CC, Liu CC, Lee YC, Huang CN, Pao JB, Huang CH: Genetic variants in
CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-
deprivation therapy. PLoS One 2012, 7(7):e41219.
55. Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M: Cdc7-Dbf4 kinase overexpression in multiple
cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia 2008, 10(9):920–931.
56. Burkhart R, Schulte D, Hu D, Musahl C, Gohring F, Knippers R: Interactions of human nuclear proteins P1Mcm3
and P1Cdc46. Europ J Biochem 1995, 228:431–438.
57. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating
concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351(9113):1393–1396.
58. Hauge C, Frodin M: RSK and MSK in MAP kinase signalling. J Cell Sci 2006, 119(Pt 15):3021–3023.
59. Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS:
RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 2007,
26(5):683–700.
60. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A,
Aldape K, Califano A, Iavarone A: The transcriptional network for mesenchymal transformation of brain
tumours. Nature 2010, 463(7279):318–325.
61. Tanaka T, Akira S, Yoshida K, Umemoto M, Yoneda Y, Shirafuji N, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T:
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity
by macrophages. Cell 1995, 80(2):353–361.
62. Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, Tsuzuki S,
Greaves M, Enver T: Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.
Science 2008, 319(5861):336–339.
63. Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK, Wagner K, Scheller M, Iwasaki H, Liu C,
Hackanson B, Akashi K, Leutz A, Rothstein TL, Plass C, Tenen DG: Lymphoid cell growth and transformation are
suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 2006, 38(1):27–37.
64. Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR: SARPs:
a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A 1997, 94(25):13636–13641.
65. van Dongen S: A cluster algorithm for graphs. Technical Report INS-R0010. Netherlands, Amsterdam: National
Research Institute for Mathematics and Computer Science; 2000.
66. Frey BJ, Dueck D: Clustering by passing messages between data points. Science 2007, 315(5814):972–976.doi:10.1186/1756-0381-6-17
Cite this article as: Petrochilos et al.: Using random walks to identify cancer-associated modules in expression
data. BioData Mining 2013 6:17.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
